CMPX: Dhuwit awis diétung saben siji saham Compass Therapeutics Corp

Compass Therapeutics develops bispecific antibodies to combat solid tumors by combining the blockade of cancer growth with an immune response. The cash per share trend visualizes the actual volume of liquidity, where 0.91 shows the level of this metric. The scientific team is effectively advancing the therapy portfolio, while management is currently prioritizing the most successful clinical programs following an analysis of interim data.
Rincian metrik komprehensif lan analitis compasstherapeutics.com (CMPX)

For Compass Therapeutics (CMPX), whose development depends on clinical trials and patent protection, the cash per share metric on GURU.Markets reflects the company's ability to fund R&D independently of macro cycles. This metric is calculated by dividing net liquidity by the number of shares outstanding, allowing investors to assess the business's margin of safety and the risk of equity dilution when seeking new financing.